Last Update 18 Apr 26

EVH: Conservative Reserves And New Contracts Will Support Future Margin Recovery

Analysts have reduced Evolent Health price targets to a range of about $4 to $8, often roughly halving prior levels. They cite lower earnings estimates, a more conservative reserve posture, and limited near term visibility on margin and leverage recovery as key factors.

Analyst Commentary

Recent research highlights a mix of optimism and caution around Evolent Health, with most analysts cutting price targets but maintaining generally constructive views on the business model and its execution risks. The reaction centers on updated earnings forecasts, reserve decisions, leverage, and visibility on profitability.

Bullish Takeaways

Bullish analysts view the more conservative reserve posture as a potential cushion, suggesting that if medical costs track in line with expectations, there could be room for reserve releases that support margins over time.
Several research notes point to significant new business as a source of potential margin improvement, framing the current earnings reset as a step that could allow the company to scale into a more profitable profile if contracts perform as expected.
Some analysts highlight that under the new CFO, there appears to be a push for greater transparency and conservatism in guidance, which they see as helpful for rebuilding credibility on earnings quality and risk management.
Even with lower price targets in the US$4 to US$8 range, bullish analysts continue to see room for upside relative to current valuation if management executes on cost control and the longer term earnings plan.

Bearish Takeaways

Bearish analysts focus on the lack of near term visibility into EBITDA and margin recovery, which makes it harder to underwrite a clear earnings trajectory and justifies lower valuation multiples in their view.
Concerns around higher leverage, with expectations that debt levels could rise to about 7x before moderating, weigh on confidence in balance sheet flexibility and may limit how much risk some investors are willing to take on the name.
Some research notes flag ongoing worries about medical cost pressures and the impact of ACA exchange membership, which they see as potential headwinds to stable margins and consistent execution.
The broad reset in price targets, often roughly halving prior levels, signals that analysts are building in more conservative assumptions around growth and profitability, reflecting a shift toward a more cautious stance on the risk or reward tradeoff.

What's in the News

Evolent Health reported a goodwill impairment of $398,000,000 for the fourth quarter ended December 31, 2025, which directly affects reported earnings for that period (Key Developments).
The company issued earnings guidance for the full year ending December 31, 2026, with expected revenue in the range of approximately $2.4b to $2.6b (Key Developments).
Together, the large goodwill impairment and the new revenue guidance provide new data points on how management is resetting the balance sheet and framing expectations for the 2026 income statement (Key Developments).

Valuation Changes

Fair Value: Model fair value remains unchanged at $5.18 per share, indicating no adjustment to the core valuation anchor.
Discount Rate: The discount rate stays at 12.33%, so the assumed risk profile and required return in the model are consistent with prior inputs.
Revenue Growth: Forecast revenue growth is effectively steady at about 20.20%, with only an immaterial rounding change in the updated figure.
Net Profit Margin: The net profit margin assumption edges lower from about 6.33% to about 6.03%, reflecting a slightly more cautious view on future profitability.
Future P/E: The future P/E multiple increases modestly from about 3.52x to about 3.70x, suggesting a small uplift in the valuation multiple applied to projected earnings.

2 views

Key Takeaways

Accelerating demand for value-based care and advanced tech platforms is boosting Evolent's market expansion, long-term revenue growth, and client retention.
Investments in AI, proprietary programs, and regulatory tailwinds are improving margins, reducing costs, and enabling profitable market share gains over legacy solutions.
Heavy reliance on uncontracted pipeline, client concentration, regulatory shifts, and rising competition create substantial risks to Evolent's revenue growth, margin stability, and market position.

Catalysts

About Evolent Health

Through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States.What are the underlying business or industry changes driving this perspective?

The shift towards value-based care and demand for advanced population health platforms is accelerating, driving Evolent's expanding addressable market, as evidenced by pipeline growth and multi-year partnerships-supporting long-term revenue growth above industry averages.
The rapid adoption of AI and digital automation is enabling Evolent to significantly reduce costs, improve quality, and enhance client outcomes, with recent operational initiatives expected to yield run-rate EBITDA improvements and margin expansion over the next 24 months.
Demographic dynamics, such as an aging U.S. population and the rising chronic disease burden, continue to increase the need for Evolent's specialty care management services, directly supporting long-term topline growth and client retention.
Ongoing investments in proprietary technology and scalable specialty programs (e.g., oncology, cardiology, MSK) are creating cross-sell opportunities and supporting operational leverage, which is likely to drive improved operating margins as revenue scales.
Legislative and payer-driven mandates for greater interoperability, streamlined prior authorization, and clinical data exchange are accelerating client adoption, positioning Evolent to win market share from legacy in-house solutions and contributing to a higher proportion of high-margin, recurring revenue in future financials.

Evolent Health Earnings and Revenue Growth

Evolent Health Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Evolent Health's revenue will grow by 20.2% annually over the next 3 years.
Analysts are not forecasting that Evolent Health will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Evolent Health's profit margin will increase from -30.9% to the average US Healthcare Services industry of 6.0% in 3 years.
If Evolent Health's profit margin were to converge on the industry average, you could expect earnings to reach $196.3 million (and earnings per share of $1.97) by about April 2029, up from -$579.4 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 3.7x on those 2029 earnings, up from -0.5x today. This future PE is lower than the current PE for the US Healthcare Services industry at 31.8x.
Analysts expect the number of shares outstanding to decline by 3.65% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 12.33%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

A significant portion of Evolent's near-term revenue growth (notably the projected $2.5 billion+ in 2026) is dependent on converting a weighted pipeline of potential deals, many of which are not yet contracted and may be delayed or downsized, introducing execution and timing risk that could negatively impact future revenue and earnings.
Evolent's ongoing shift to enhanced contract terms for the Performance Suite-prioritizing downside risk protection over upside-may cap earnings potential, especially if the new risk corridors materially limit profitability as utilization trends become more volatile, thereby compressing net margins over time.
Heavy client concentration in large national payers such as Aetna exposes Evolent to the risk that the loss, underperformance, or delayed expansion with any single client could have an outsized negative effect on revenue and earnings visibility.
Regulatory and policy uncertainty surrounding Medicaid and Affordable Care Act (exchange) populations-including potential loss of subsidies or state-level enrollment changes-could drive meaningful declines in covered lives and corresponding EBITDA headwinds (as noted, a 5% membership reduction equates to an $8–10 million EBITDA impact), limiting incremental revenue growth and pressuring operating results.
Intensifying competition and accelerating technological advances by major incumbents and digital health disruptors (e.g., UnitedHealth/Optum, CVS/Aetna) may increase pricing pressure, raise the required pace of investment in AI and analytics (with uncertain ROI), and risk eroding Evolent's technological advantage, thereby pressuring future net margins and market share.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $5.18 for Evolent Health based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $8.0, and the most bearish reporting a price target of just $3.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $3.3 billion, earnings will come to $196.3 million, and it would be trading on a PE ratio of 3.7x, assuming you use a discount rate of 12.3%.
Given the current share price of $2.84, the analyst price target of $5.18 is 45.2% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Evolent Health?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Value-based Care And Digital Automation Will Expand Future Opportunities